Arcutis Biotherapeutics ARQT

$ 10.18 -0.59%

Quarterly report 2024-Q3
added 11-06-2024

Arcutis Biotherapeutics Balance Sheet 2011-2024 | ARQT

Annual Balance Sheet Arcutis Biotherapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	114 M	145 M	-25.2 M	-	-63 M	-39.4 M	-3.42 M	-	-	-	-	-	-
Long Term Debt	202 M	198 M	72.4 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	735 K	657 K	433 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	167 M	72.4 M	8.12 M	-	-	-	-	-	-
Total Current Liabilities	46.7 M	37.8 M	33.3 M	22.6 M	-	-	-	-	-	-	-	-	-
Total Liabilities	253 M	240 M	110 M	27.6 M	172 M	75.1 M	8.81 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-982 M	-720 M	-408 M	-202 M	-66.3 M	-24.3 M	-5.02 M	-	-	-	-	-	-
Total Assets	341 M	449 M	408 M	298 M	107 M	51.1 M	3.82 M	-	-	-	-	-	-
Cash and Cash Equivalents	88.4 M	53.6 M	98 M	66.6 M	63.3 M	39.4 M	-	-	-	-	-	-	-
Book Value	88.7 M	210 M	298 M	271 M	-65 M	-24 M	-4.99 M	-	-	-	-	-	-
Total Shareholders Equity	88.7 M	210 M	298 M	271 M	-65 M	-24 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Arcutis Biotherapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	105 M	204 M	203 M	202 M	201 M	200 M	199 M	198 M	197 M	-	72.7 M	72.4 M	4.92 M	5.03 M	5.05 M	-	4.96 M	4.96 M	4.96 M	129 K	129 K	129 K	129 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	281 M	258 M	254 M	253 M	246 M	240 M	240 M	240 M	238 M	-	110 M	110 M	24 M	18.4 M	20.4 M	27.6 M	27.6 M	27.6 M	27.6 M	5.55 M	5.55 M	5.55 M	5.55 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.11 B	-1.07 B	-1.02 B	-982 M	-916 M	-871 M	-800 M	-720 M	-648 M	-	-473 M	-408 M	-337 M	-280 M	-238 M	-202 M	-202 M	-202 M	-202 M	-66.3 M	-66.3 M	-66.3 M	-66.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	437 M	445 M	479 M	341 M	293 M	321 M	379 M	449 M	509 M	-	364 M	408 M	387 M	433 M	471 M	298 M	298 M	298 M	298 M	107 M	107 M	107 M	107 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	135 M	84.3 M	190 M	88.4 M	108 M	106 M	82.3 M	53.6 M	82.8 M	62.7 M	71 M	96.4 M	53.3 M	89.1 M	289 M	65.1 M	65.1 M	65.1 M	65.1 M	63.3 M	63.3 M	63.3 M	63.3 M	39.4 M	-	-	-	3.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	157 M	186 M	225 M	88.7 M	46.7 M	80.5 M	140 M	210 M	271 M	-	254 M	298 M	363 M	414 M	451 M	271 M	271 M	271 M	271 M	101 M	101 M	101 M	101 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	157 M	186 M	225 M	88.7 M	46.7 M	80.5 M	140 M	210 M	271 M	195 M	254 M	298 M	363 M	414 M	451 M	271 M	271 M	271 M	271 M	-65 M	-65 M	-65 M	-65 M	-24 M	-	-	-	-4.99 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency